DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Phase III.
Clinical trial using daclizumab for relapsing-remitting multiple sclerosis inititated.
Immunotherapy 2010;
2: 437
We do not assume any responsibility for the contents of the web pages of other providers.